See the DrugPatentWatch profile for nivolumab
The Main Manufacturers of Nivolumab: A Comprehensive Overview
Nivolumab, also known as Opdivo, is a monoclonal antibody used in the treatment of various types of cancer, including melanoma, lung cancer, kidney cancer, and others. It works by inhibiting the PD-1 protein on T-cells, allowing them to attack cancer cells more effectively. In this article, we will explore the main manufacturers of nivolumab and their roles in the development and commercialization of this life-saving medication.
History of Nivolumab Development
Nivolumab was first developed by Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, in collaboration with Bristol-Myers Squibb (BMS), an American multinational pharmaceutical company. The development of nivolumab was a result of a strategic partnership between the two companies, which aimed to leverage their combined expertise in oncology research and development.
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company that was founded in 1948. The company has a long history of developing innovative medications, including nivolumab. According to DrugPatentWatch.com, Ono Pharmaceutical Co., Ltd. holds the original patent for nivolumab in Japan, which was granted in 2014.
Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS) is an American multinational pharmaceutical company that was founded in 1887. The company has a rich history of developing innovative medications, including nivolumab. BMS played a crucial role in the development and commercialization of nivolumab, and the company holds the patent for nivolumab in the United States, which was granted in 2014.
Other Manufacturers of Nivolumab
In addition to Ono Pharmaceutical Co., Ltd. and BMS, there are several other manufacturers of nivolumab, including:
* Teva Pharmaceutical Industries Ltd.: Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company that has a license agreement with BMS to manufacture and distribute nivolumab in certain countries.
* Sandoz International GmbH: Sandoz International GmbH is a Swiss multinational pharmaceutical company that has a license agreement with BMS to manufacture and distribute nivolumab in certain countries.
* Mylan N.V.: Mylan N.V. is an American multinational pharmaceutical company that has a license agreement with BMS to manufacture and distribute nivolumab in certain countries.
Key Takeaways
* Nivolumab was developed by Ono Pharmaceutical Co., Ltd. and BMS through a strategic partnership.
* Ono Pharmaceutical Co., Ltd. holds the original patent for nivolumab in Japan, while BMS holds the patent for nivolumab in the United States.
* Several other manufacturers, including Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, and Mylan N.V., have a license agreement with BMS to manufacture and distribute nivolumab in certain countries.
Conclusion
Nivolumab is a life-saving medication that has revolutionized the treatment of various types of cancer. The development and commercialization of nivolumab involved a strategic partnership between Ono Pharmaceutical Co., Ltd. and BMS, as well as several other manufacturers. Understanding the main manufacturers of nivolumab is essential for patients, healthcare professionals, and pharmaceutical companies alike.
Key Takeaways
* Nivolumab is a monoclonal antibody used in the treatment of various types of cancer.
* Ono Pharmaceutical Co., Ltd. and BMS developed nivolumab through a strategic partnership.
* Several other manufacturers have a license agreement with BMS to manufacture and distribute nivolumab in certain countries.
FAQs
1. Q: Who developed nivolumab?
A: Nivolumab was developed by Ono Pharmaceutical Co., Ltd. and BMS through a strategic partnership.
2. Q: Who holds the patent for nivolumab in Japan?
A: Ono Pharmaceutical Co., Ltd. holds the original patent for nivolumab in Japan.
3. Q: Who holds the patent for nivolumab in the United States?
A: BMS holds the patent for nivolumab in the United States.
4. Q: Who are the other manufacturers of nivolumab?
A: Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, and Mylan N.V. are among the other manufacturers of nivolumab.
5. Q: What is the mechanism of action of nivolumab?
A: Nivolumab works by inhibiting the PD-1 protein on T-cells, allowing them to attack cancer cells more effectively.
Sources:
1. Ono Pharmaceutical Co., Ltd. (2014). Patent for nivolumab in Japan.
2. Bristol-Myers Squibb (2014). Patent for nivolumab in the United States.
3. DrugPatentWatch.com. (n.d.). Nivolumab (Opdivo) patent information.
4. Teva Pharmaceutical Industries Ltd. (n.d.). License agreement with BMS to manufacture and distribute nivolumab.
5. Sandoz International GmbH (n.d.). License agreement with BMS to manufacture and distribute nivolumab.
6. Mylan N.V. (n.d.). License agreement with BMS to manufacture and distribute nivolumab.
Note: The information provided in this article is based on publicly available data and may not be up-to-date or accurate. It is essential to consult with a healthcare professional or a reliable source for the most current information on nivolumab and its manufacturers.